D. Boral Capital Maintains Buy on Cormedix, Maintains $14 Price Target

CorMedix Inc. -1.38%

CorMedix Inc.

CRMD

7.13

-1.38%

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ: CRMD) with a Buy and maintains $14 price target.